A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments

Overview of attention for article published in BMC Cancer, March 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 39 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 3 news stories from 1 outlets.

CytRx's Controversial Saga Continues

Seeking Alpha, 02 May 2017

CytRx (NASDAQ: CYTR ) Corporation is a clinical-stage, biopharmaceutical company focused on discovering, developing, and…

Unscrubbed Aldoxorubicin Phase 3 Pivotal Trial Data Approaches Maturity: The Dirty Truth

Seeking Alpha, 02 Dec 2016

CytRx Corporation (NASDAQ: CYTR ) has released unscrubbed data of its phase 3 pivotal trial for Aldoxorubicin as a monotherapy…

CytRx's Aldoxorubicin Phase 3 Trial: A High EV Scenario

Seeking Alpha, 29 Jun 2016

Clinical Activity of Aldoxorubicin Monotherapy There are any number of adjuvant tries in clinical oncology today.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.